Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth L Siegler

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Frontiers in Immunology|September 28, 2020
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel TherapiesElizabeth L Siegler, Saad S Kenderian
Cancer Research|March 12, 2026
The Conflicting Role of Myeloid Cells in CAR-T Cell TherapyGrace DeFranco, Elizabeth L Siegler, Saad S Kenderian
Clinical Hematology International|January 7, 2021
CART Cell Toxicities: New Insight into Mechanisms and ManagementAnas Zahid, Elizabeth L Siegler, Saad S Kenderian
Leukemia|August 25, 2023
Who wins the combat, CAR or TCR?Kun Yun, Elizabeth L Siegler, Saad S Kenderian
Cell Stem Cell|August 4, 2018
Off-the-Shelf CAR-NK Cells for Cancer ImmunotherapyElizabeth L Siegler, Yanni Zhu, Pin Wang, et al.
Neurologic Clinics|October 12, 2020
A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell ImmunotherapyMichael W Ruff, Elizabeth L Siegler, Saad S Kenderian
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 27, 2021
CRISPR Takes the Front Seat in CART-Cell DevelopmentClaudia Manriquez-Roman, Elizabeth L Siegler, Saad S Kenderian
Journal of Immunology (Baltimore, Md. : 1950)|April 10, 2025
The road ahead for chimeric antigen receptor T cellsCarli M Stewart, Elizabeth L Siegler, Saad S Kenderian
Current Hematologic Malignancy Reports|February 10, 2023
CAR-T Cell Therapy: the Efficacy and Toxicity BalanceKaran L Chohan, Elizabeth L Siegler, Saad S Kenderian
Cancer Immunology Research|December 1, 2025
The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell TherapyCarli M Stewart, Elizabeth L Siegler, Saad S Kenderian
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|September 28, 2020
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel TherapiesElizabeth L Siegler, Saad S Kenderian
Cancer Research|March 12, 2026
The Conflicting Role of Myeloid Cells in CAR-T Cell TherapyGrace DeFranco, Elizabeth L Siegler, Saad S Kenderian
Clinical Hematology International|January 7, 2021
CART Cell Toxicities: New Insight into Mechanisms and ManagementAnas Zahid, Elizabeth L Siegler, Saad S Kenderian
Leukemia|August 25, 2023
Who wins the combat, CAR or TCR?Kun Yun, Elizabeth L Siegler, Saad S Kenderian
Cell Stem Cell|August 4, 2018
Off-the-Shelf CAR-NK Cells for Cancer ImmunotherapyElizabeth L Siegler, Yanni Zhu, Pin Wang, et al.
Neurologic Clinics|October 12, 2020
A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell ImmunotherapyMichael W Ruff, Elizabeth L Siegler, Saad S Kenderian
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 27, 2021
CRISPR Takes the Front Seat in CART-Cell DevelopmentClaudia Manriquez-Roman, Elizabeth L Siegler, Saad S Kenderian
Journal of Immunology (Baltimore, Md. : 1950)|April 10, 2025
The road ahead for chimeric antigen receptor T cellsCarli M Stewart, Elizabeth L Siegler, Saad S Kenderian
Current Hematologic Malignancy Reports|February 10, 2023
CAR-T Cell Therapy: the Efficacy and Toxicity BalanceKaran L Chohan, Elizabeth L Siegler, Saad S Kenderian
Cancer Immunology Research|December 1, 2025
The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell TherapyCarli M Stewart, Elizabeth L Siegler, Saad S Kenderian
Pageof 4